A Neural Network-Enabled, Enzymatic cfDNA Methylation Assay for Colorectal Cancer Early Detection
A new blood test can detect colorectal cancer early by analyzing DNA fragments, showing promise for non-invasive screening in larger studies.
Weill Cornell developed a non-NGS cfDNA methylation assay targeting 40 CpG regions with neural network age integration, achieving 92.3% CRC detection sensitivity in 216 plasma samples. Early-stage performance reached 100% sensitivity at 97.4% specificity, though limited early-stage n requires prospective validation in larger cohorts.
What the study was
- Study design
- Retrospective validation cohort study
- Population
- CRC cases and healthy controls (plasma)
- Sample size
- 216
- Category
- Early Detection
- Maturity
- Validated
- Journal
- Cancer Prevention Research
Why it surfaced
Non-NGS cfDNA methylation + neural network achieves 100% early-stage CRC sensitivity in validation — potentially scalable, cost-effective population screening tool for a major unmet early-detection need.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.